All News

Jakob Jensen, PhD, professor in the Department of Communication at the University of Utah and member of the Huntsman Cancer Institute, discusses how the beliefs and perceptions of cancer among adults living in rural areas compared to those of adults living in urban areas.

Filgrastim-ayow is indicated for the treatment of neutropenia, which is commonly experienced by patients receiving chemotherapy.

Although biologic changes may occur in the body that affect the brain, nonbiologic changes, such as social isolation, can also be a part of it but the reasons are not completely clear, according to the study.

Gauging patients’ satisfaction with pharmacy services provides an opportunity perhaps for improved patient outcomes in certain situations.

Thomasina Morris, RPh, MHA, BCOP, pharmacist at Moffitt Cancer Center, discusses how dosing for rucaparib treatment is assessed to treat patients with ovarian cancer.

At week 4, there was about a 61.6% decrease for individuals with hypercholesterolemia who do not attain low-density lipoprotein cholesterol and/or are intolerant to other lipid-lowering drugs.

During spring to fall 2020 related visits to emergency departments declined compared with a year earlier, study results show.

The agency has given the greenlight to the abbreviated new drug application for the overdose-reversal medication.

The CAR T-cell therapy CYAD-101 was being evaluated in combination with FOLFOX followed by pembrolizumab (Keytruda) in patients with unresectable metastatic colorectal cancer.

Rocuronium bromide is indicated as an adjunct to general anesthesia and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Odor-Eaters foot powder removes foot odor and offers possible wetness protection.

Lakyn Husinka, PharmD, discussed new treatment options and pharmacists' role in treating patients with breast cancer.

PrEP involves taking emtricitabine/tenofovir (Truvada or Descovy) to prevent high-risk individuals from contracting HIV.

The researchers aimed to identify the factors that may influence the risk of statin intolerance.

Breadth, intensity of vertical integration keeps growing, leaving pharmacies' future role uncertain.

Erenumab (Aimovig) was the first anti-CGRP agent approved by the FDA for migraine prophylaxis.

Shingles can cause significant pain and, in some rare instances, can be life-threatening.

The agency addresses the inclusion of older individuals in cancer-studies, the designing and conducting of multiple expansion cohorts, and the expedited development of biologics and drugs.

The median survival time for individuals with SCC and treated with Merck’s pembrolizumab was 13.9 months compared with 8.8 months in the control arm.

Jakob Jensen, PhD, professor in the Department of Communication at the University of Utah and member of the Huntsman Cancer Institute, discusses rural residents’ beliefs and perceptions of cancer-related information in comparison with those of urban residents.

Suvorexant (Belsomra) is indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

Ocuvite treats vitamin deficiency due to poor diet, certain illnesses, or during pregnancy.

Thomasina Morris, RPh, MHA, BCOP, pharmacist at Moffitt Cancer Center, discusses the efficacy of rucaparib for approved indications based on clinical trial results.

As we head into March, things appear to be looking up on the COVID-19 front.

Zachary Nelson, PharmD, BCIDP, BCPS, discussed the past 2 influenza seasons and how they could help predict vaccination and illness rates.

A supplemental application was also submitted for an oral suspension formulation to provide an alternative administration option for children.

David Zgarrick, PhD, FAPhA, professor in the department of pharmacy and health systems sciences at Northeastern University, also addresses what the future of the pharmacy profession could look like.

Links of chain mail are arranged in the bacteria to form a pattern that prevents molecules from entering the cell.

Pacritinib becomes the first treatment approved to specifically address the needs of patients with cytopenic myelofibrosis.

Majority of heavily pretreated patients with multiple myeloma administered ciltacabtagene autoleucel (cilta-cel; Carvykti) achieved deep responses after 18-months follow-up.